BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-1758 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-1758\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07599670-671@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:ABBV-1758: Phase 1/2 readout est. (NCT07599670)
DESCRIPTION:ABBV-1758\, phase 1/2\, Alzheimer's Disease.\nStudy: A Study to
  Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intr
 avenous Injections in Participants With Alzheimer's Disease\nEstimated pri
 mary completion: October 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abbv-1758#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07599670
URL:https://assetmemo.bio/drug/abbv-1758#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
